左西孟旦与米力农治疗心力衰竭的效果对照分析及研究  

Comparative analysis and research of effects by levosimendan and milrinone in the treatment of heart failure

作　　者：黄梦红 肖飞 

机构地区：[1]昌乐县人民医院心内一科,262400

出　　处：《中国实用医药》2016年第32期121-123,共3页China Practical Medicine

摘　　要：目的探讨左西孟旦与米力农治疗心力衰竭的效果对照。方法 76例心力衰竭患者,随机分为M组和Z组,各38例。M组用米力农治疗;Z组用左西孟旦治疗。比较两组患者心力衰竭治疗总有效率;治疗前后左室射血分数、左室舒张末和收缩末内径、血清氨基末端B型钠利尿肽前体(NTpro BNP)水平、药物不良反应率。结果 Z组患者心力衰竭治疗总有效率为97.37%,显著高于M组的78.95%,差异有统计学意义(P<0.05)。治疗前两组患者左室射血分数、左室舒张末和收缩末内径、血清NT-pro BNP水平比较,差异无统计学意义(P>0.05)。治疗后两组患者左室射血分数、左室舒张末和收缩末内径、血清NT-pro BNP水平显著优于治疗前,差异有统计学意义(P<0.05);且Z组左室射血分数升高幅度更大,左室舒张末和收缩末内径、血清NT-pro BNP水平降低幅度更大,差异有统计学意义(P<0.05)。Z组患者药物不良反应率为2.63%,显著低于M组的21.05%,差异有统计学意义(P<0.05)。结论左西孟旦与米力农治疗心力衰竭均有一定效果,但左西孟旦效果更好,可更好提高左室射血分数,延缓心室重构,且安全性更高,值得推广应用。Objective To investigate effects by levosimendan and milrinone in the treatment of heart failure. Methods A total of 76 patients with heart failure were randomly divided into group M and group Z, with 38 cases in each group. Group M received milrinone for treatment, and group Z received levosimendan instead. Comparison was made on total effective rate in treating heart failure, left ventricular ejection fraction, left ventricular end diastolic diameter, left Ventricular end systolic diameter, serum amino-terminal pro-brain natriuretic peptide （NT-proBNP） level and incidence of adverse drug reactions. Results Group Z had obviously higher total effective rate in treating heart failure as 97.37% than 78.95% in group M, and the difference had statistical significance （P〈0.05）. There was no statistically significant difference of left ventricular ejection fraction, left ventricular end diastolic diameter, left ventricular end systolic diameter, serum NT-proBNP level between the two groups before treatment （P〉O;05）. After treatment, both groups had better left ventricular ejection fraction, left ventricular end diastolic diameter, left ventrieular end systolic diameter, serum NT-proBNP level than those before treatment, and the difference had statistical significance （P〈O.05）. Group Z had higher increasing range in left ventricular ejection fraction and decreasing range in left ventricular end diastolic diameter, left ventricular end systolic diameter, serum NT-proBNP level than group M, and the difference had statistical significance （P〈0.05）. Group Z had obviously＇lower incidence of adverse drug reactions as 2.63% than 21.05% of group M, and the difference had statistical significance （P〈0.05）. Conclusion Levosimendan and milrinone all show certain effect in treating heart failure, while levosimendan contains better effeft, improves left ventricular ejection fraction and delays ventricular remodeling, along with high safety. It is worth promoting and applying.

关 键 词：左西孟旦 米力农 心力衰竭 效果 

分 类 号：R541.6[医药卫生—心血管疾病]